News

Correspondence with Nature Reviews – "Tuberculosis – drugs in the 2016 development pipeline"


10 Mar 2017
by Working Group

WGND Co-chair, Barbara Laughon, and Sequella Inc. CEO, Carol Nacy, co-authored a correspondence to Nature Reviews regarding the October 2016 Article, “Tuberculosis”.

“In their recent Primer article (Tuberculosis. Nat. Rev. Dis. Primers 2, 16076 (2016))1, Madhukar Pai and colleagues give an important and comprehensive update on the advances made in  epidemiology, diagnosis, prevention and treatment for combatting the global tuberculosis (TB) epidemic. The Primer included the global TB drug pipeline (Figure 5) that represented the status of the field as of April 2016. However, several important new developments were reported at two major scientific conferences later in 2016: the EMBO Conference Tuberculosis 2016 in Paris, France, 19–23 September 2016 (http://www.tuberculosis2016.org), and the 47th Union World Congress on Lung Health and associated meetings in Liverpool, UK, 26–29 October 2016 (http://liverpool.worldlunghealth.org/). We believe that updates to the 2016 status of the TB drug pipeline would be of interest to readers of the journal…”

 

Continue reading here: http://www.nature.com/articles/nrdp201715

More News
29 Nov 2018
On December 6, 2018, at 7AM EST, TREAT TB will host a capacity building webinar on community engagement in MDR-TB clinical trials. It will feature a presentation from Ezio Tavora dos Santos Filho, STREAM Community Engagement Coordinator from REDE-TB , followed by a question and answer session. The...
2 Oct 2018
The first ever U.N. General Assembly’s high-level meeting (UNHLM) on tuberculosis took place on Wednesday, September 26 in New York City. The U.N. delegation of countries agreed to ambitious targets including a commitment to finding 40 million undiagnosed cases of TB by the end of 2022 and...
18 Sep 2018
In an article written by Lucica Ditiu, Executive Director, Stop TB Partnership, and Jacqueline Huh, Head, Strategic Initiatives & Innovative Financing, Stop TB, the 'valleys of death' that hold back TB new tools innovation are discussed. These two valleys occur between new tool development and...